Journal Watch · Frontiers in Immunology · 2026

Why are long-lived plasma cells long-lived?

In human health, new insights into how LLPCs survive and differentiate will impact the development of robust and long-lasting vaccinations, as well as with treatment of autoantibody-mediate autoimmune diseases and PC malignancies such as multiple myeloma (MM)-as these malignancies remain dependent on many of the same survival pathways as their nonmalignant LLPC counterparts.

Reinke JG, Schorr C, Lee KPFrontiers in Immunology4 min readPharma relevance 50/100

DOI: 10.3389/fimmu.2026.1785563PMID: 42183219Study type: research study

TL;DR

In human health, new insights into how LLPCs survive and differentiate will impact the development of robust and long-lasting vaccinations, as well as with treatment of autoantibody-mediate autoimmune diseases and PC malignancies such as multiple myeloma (MM)-as these malignancies remain dependent on many of the same survival pathways as their nonmalignant LLPC counterparts.

Key findings

  • However, the possibility of repeated antigen-driven generation of a large number of highly metabolically active long-lived cells is problematic for a resource-constrained organism, and it is now clear that LLPC numbers are constrained by a limited number of specialized LLPC niches in the bone marrow and other tissues.
  • LLPCs are not intrinsically long-lived but rely on interactions with the LLPC niche to maintain their longevity.
  • For example, activation of the CD28 receptor on LLPC by its ligands CD80/CD86 on dendritic cells (DC) in the LLPC niche results in augmented metabolism through enhanced lipophagy, intracellular long chain fatty acid availability, oxidative phosphorylation, increased mitochondrial mass and function that are necessary for LLPC survival.
  • CD28 activation is essential for the survival of LLPC but not for SLPC, supporting the concept that enhancement of LLPC metabolic capacity by interactions with its niche plays a key role in LLPC longevity.
  • In human health, new insights into how LLPCs survive and differentiate will impact the development of robust and long-lasting vaccinations, as well as with treatment of autoantibody-mediate autoimmune diseases and PC malignancies such as multiple myeloma (MM)-as these malignancies remain dependent on many of the same survival pathways as their nonmalignant LLPC counterparts.

What they did

SLPCs vs. LLPCs. Evidence suggests that although LLPC and SLPC have similar gene transcriptional profiles they differ significantly in their metabolic profiles-likely due to the demands of prolonged continuous antibody production in LLPC. These metabolic changes include increased uptake of metabolic substrates, increased mitochondrial mass/function and enhanced fuel availability via lipophagy, and enhanced proteostasis to remove misfolded proteins.

Full abstract (original)

Background: Long-Lived Plasma Cells (LLPCs) are an integral part of long-term protective humoral immunity. They can live for decades, unlike Short-Lived Plasma Cells (SLPCs), and continuously produce antibody regardless of antigen stimulation, unlike Memory B Cells (MBCs). LLPCs are critical for the sustained protective immunity against pathogens that are only intermittently present in a population but can cause significant morbidity/mortality when active-such as epidemic diseases. What drives B cell differentiation specifically to the LLPC lineage is still not fully understood; there is conflicting information on what drives the fate decisions for MBCs vs.

What they did: SLPCs vs. LLPCs. Evidence suggests that although LLPC and SLPC have similar gene transcriptional profiles they differ significantly in their metabolic profiles-likely due to the demands of prolonged continuous antibody production in LLPC. These metabolic changes include increased uptake of metabolic substrates, increased mitochondrial mass/function and enhanced fuel availability via lipophagy, and enhanced proteostasis to remove misfolded proteins.

Results & conclusions: However, the possibility of repeated antigen-driven generation of a large number of highly metabolically active long-lived cells is problematic for a resource-constrained organism, and it is now clear that LLPC numbers are constrained by a limited number of specialized LLPC niches in the bone marrow and other tissues. LLPCs are not intrinsically long-lived but rely on interactions with the LLPC niche to maintain their longevity. For example, activation of the CD28 receptor on LLPC by its ligands CD80/CD86 on dendritic cells (DC) in the LLPC niche results in augmented metabolism through enhanced lipophagy, intracellular long chain fatty acid availability, oxidative phosphorylation, increased mitochondrial mass and function that are necessary for LLPC survival. CD28 activation is essential for the survival of LLPC but not for SLPC, supporting the concept that enhancement of LLPC metabolic capacity by interactions with its niche plays a key role in LLPC longevity. In human health, new insights into how LLPCs survive and differentiate will impact the development of robust and long-lasting vaccinations, as well as with treatment of autoantibody-mediate autoimmune diseases and PC malignancies such as multiple myeloma (MM)-as these malignancies remain dependent on many of the same survival pathways as their nonmalignant LLPC counterparts.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1785563 · PubMed 42183219.

Why it matters for pharma & biotech

  • Directly relevant to teams in vaccines — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: vaccines

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

In human health, new insights into how LLPCs survive and differentiate will impact the development of robust and long-lasting vaccinations, as well as with treatment of autoantibody-mediate autoimmune diseases and PC malignancies such as multiple myeloma (MM)-as these malignancies remain dependent on many of the same survival pathways as their nonmalignant LLPC counterparts.

What type of study is this?

It is a research study, published in Frontiers in Immunology in 2026. SLPCs vs.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1785563. PubMed ID: 42183219. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Reinke JG, Schorr C, Lee KP. Why are long-lived plasma cells long-lived?. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1785563.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/why-are-long-lived-plasma-cells-long-lived-785563/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides